Shares of Minerva Neurosciences Inc. (NASDAQ:NERV) traded down 3.6% on Thursday . The stock traded as low as $10.17 and last traded at $10.25, with a volume of 150,662 shares traded. The stock had previously closed at $10.63.

Several analysts have weighed in on the stock. Zacks Investment Research raised shares of Minerva Neurosciences from a “sell” rating to a “hold” rating in a research note on Thursday, July 7th. Jefferies Group reissued a “buy” rating and issued a $17.00 price target (up from $10.00) on shares of Minerva Neurosciences in a research note on Friday, May 27th. Finally, JMP Securities boosted their price target on shares of Minerva Neurosciences from $10.00 to $17.00 in a research note on Thursday, May 26th.

The company’s 50-day moving average is $10.71 and its 200 day moving average is $6.88. The stock’s market capitalization is $287.24 million.

Minerva Neurosciences (NASDAQ:NERV) last posted its quarterly earnings data on Tuesday, May 3rd. The biopharmaceutical company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.04. On average, analysts predict that Minerva Neurosciences Inc. will post ($1.05) EPS for the current year.

In other news, Director David Kupfer acquired 55,635 shares of Minerva Neurosciences stock in a transaction that occurred on Tuesday, June 21st. The stock was purchased at an average price of $10.84 per share, for a total transaction of $603,083.40. Following the purchase, the director now directly owns 209,188 shares in the company, valued at approximately $2,267,597.92. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Minerva Neurosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company’s product portfolio include MIN-101 for the treatment of schizophrenia; MIN-117 for the treatment of major depressive disorder (MDD); MIN-202 (also known as JNJ-42847922) for the treatment of insomnia disorder and adjunctive MDD, and MIN-301 for the treatment of Parkinson’s disease.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.